Clinical Medicine III.
Introduction: Perinatal hemorrhagic stroke (PHS) carries the risk of significant long-term neurodevelopmental burden on survivors. A better understanding of the relationship between the MRI findings, clinical risk factors and outcome is of major interest to caregivers and families.
Aims: To assess the long-term neurodevelopmental outcome of term neonates diagnosed with PHS and investigate the associations among brain territorial involvement, clinical risk factors and neurodevelopmental outcomes.
Methods: We conducted a population-based study enrolling 55 term neonates with PHS confirmed by MRI born between 2007-2017. Long-term neurodevelopmental outcome was assessed using the Bayley Scales of Infant Development-II, the Brunet-Lézine test and the Binet Intelligence scales-V.
Results: Follow-up was available in 50 (91%) of the infants, at a median age of 60 months [IQR: 35,88]. Forty (40)% of the infants developed according to population norms and developmental disabilities were diagnosed less frequently among neonates with frontal lobe PHS. In a multivariable model, parietal lobe PHS increased the risk for cerebral palsy (OR:6.7 95%CI:1.1-41.4) and cognitive impairment (OR:23.6 95%CI:2.9-194.9), while the involvement of the thalamus and/or basal ganglia was associated with epilepsy (OR:7.0 95%CI:1.3-37.7). Seizures on admission were associated with epilepsy (OR:10.8 95%CI:1.8-64.3). Patients with PHS affecting multiple lobes had poor prognosis.
Conclusion: Parietal lobe hemorrhage, the involvement of the thalamus/basal ganglia, PHS affecting multiple lobes and seizures were independent predictors of chronic neurodevelopmental sequelae, suggesting that the interplay of stroke territorial involvement and clinical risk factors influence the outcome of PHS.
Funding: Financial support for this work was provided by the Semmelweis University grant (EFOP-3.6.3-VEKOP-16-2017-00009) and by the New National Excellence Program of the Ministry for Innovation and Technology from the Source of the National Research, Development and Innovation Fund (ÚNKP-21-3-II-SE-5).